Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures

Pulmonary exacerbations are a major cause of morbidity in cystic fibrosis (CF) and likely contribute to lung function decline. Exacerbations are often associated with characteristic airway bacteria [CF related bacteria (CFRB)]. However, some patients do not have CFRB detected by culture during exacerbations.

[1]  S. Aaron,et al.  The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. , 2010, Chest.

[2]  G. Döring,et al.  Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  J. Harris,et al.  Characteristics of Cystic Fibrosis Patients with Pulmonary Exacerbation and No Detectable CF Airway Pathogens. , 2009, ATS 2009.

[4]  M. Bugiani,et al.  Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. , 2009, Respiratory medicine.

[5]  M. Surette,et al.  A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients , 2008, Proceedings of the National Academy of Sciences.

[6]  P. Sly,et al.  Disease surveillance using bronchoalveolar lavage. , 2008, Paediatric respiratory reviews.

[7]  M. Wolfgang,et al.  Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. , 2008, American journal of respiratory and critical care medicine.

[8]  B. Kerem,et al.  Consensus on the Use and Interpretation of Cystic Fibrosis Mutation Analysis in Clinical Practice , 2022 .

[9]  H. Endeman,et al.  Clinical features predicting failure of pathogen identification in patients with community acquired pneumonia , 2008, Scandinavian journal of infectious diseases.

[10]  J. Elborn,et al.  Exacerbations in cystic fibrosis: 3 · Management , 2007, Thorax.

[11]  N. Pace,et al.  Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis , 2007, Proceedings of the National Academy of Sciences.

[12]  S. Bell,et al.  Exacerbations in cystic fibrosis: 2 · Prevention , 2007, Thorax.

[13]  R. Kronmal,et al.  Advancing outcome measures for the new era of drug development in cystic fibrosis. , 2007, Proceedings of the American Thoracic Society.

[14]  Charles A. Johnson,et al.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. , 2007, The Journal of pediatrics.

[15]  J. Kastelik,et al.  Ten years of viral and non-bacterial serology in adults with cystic fibrosis , 2007, Epidemiology and Infection.

[16]  L. Saiman,et al.  Nontuberculous Mycobacteria in Cystic Fibrosis , 2007, The Pediatric infectious disease journal.

[17]  C. Goss,et al.  Exacerbations in cystic fibrosis · 1: Epidemiology and pathogenesis , 2007, Thorax.

[18]  L. Nielsen,et al.  Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic , 2006, Pediatric pulmonology.

[19]  G. Rogers,et al.  Use of 16S rRNA Gene Profiling by Terminal Restriction Fragment Length Polymorphism Analysis To Compare Bacterial Communities in Sputum and Mouthwash Samples from Patients with Cystic Fibrosis , 2006, Journal of Clinical Microbiology.

[20]  M. Surette,et al.  Cystic fibrosis: a polymicrobial infectious disease. , 2006, Future microbiology.

[21]  M. Desai,et al.  Compliance of Clinical Microbiology Laboratories in the United States with Current Recommendations for Processing Respiratory Tract Specimens from Patients with Cystic Fibrosis , 2006, Journal of Clinical Microbiology.

[22]  M. Rosenfeld,et al.  Cystic fibrosis pulmonary exacerbations. , 2006, The Journal of pediatrics.

[23]  V. Raia,et al.  BMC Infectious Diseases BioMed Central Research article , 2006 .

[24]  R. Gibson,et al.  Pathophysiology and management of pulmonary infections in cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.

[25]  P. Gilligan,et al.  Laboratory Aspects of Management of Chronic Pulmonary Infections in Patients with Cystic Fibrosis , 2003, Journal of Clinical Microbiology.

[26]  J. Carlin,et al.  Cost of delayed childbearing , 2002, Archives of disease in childhood.

[27]  J. Burns,et al.  Utility of Gram Staining for Evaluation of the Quality of Cystic Fibrosis Sputum Samples , 2002, Journal of Clinical Microbiology.

[28]  T. Liou,et al.  Predictive 5-year survivorship model of cystic fibrosis. , 2001, American journal of epidemiology.

[29]  J. Carlin,et al.  Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis. , 2001, The European respiratory journal.

[30]  J. Emerson,et al.  Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis , 1999, Pediatric pulmonology.

[31]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[32]  J. Emerson,et al.  Microbiology of sputum from patients at cystic fibrosis centers in the United States. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  B. Ramsey,et al.  Management of pulmonary disease in patients with cystic fibrosis. , 1996, The New England journal of medicine.

[34]  J. Summersgill,et al.  Chlamydia pneumoniae infection in patients with cystic fibrosis. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  R. van Furth,et al.  Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. , 1995, Thorax.

[36]  D. Dockery,et al.  Pulmonary function growth velocity in children 6 to 18 years of age. , 1993, The American review of respiratory disease.

[37]  R. Gibson,et al.  Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. , 1991, The American review of respiratory disease.

[38]  P. Gilligan,et al.  Microbiology of airway disease in patients with cystic fibrosis , 1991, Clinical Microbiology Reviews.

[39]  R. Turner,et al.  Clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections , 1990, The Journal of Pediatrics.

[40]  W. Warwick,et al.  Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. , 1990, The American review of respiratory disease.

[41]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[42]  M. Dodd,et al.  Infective respiratory exacerbations in young adults with cystic fibrosis: role of viruses and atypical microorganisms. , 1989, Thorax.

[43]  N. Høiby,et al.  RESPIRATORY INFECTIONS IN CYSTIC FIBROSIS PATIENTS CAUSED BY VIRUS, CHLAMYDIA AND MYCOPLASMA–POSSIBLE SYNERGISM WITH PSEUDOMONAS AERUGINOSA , 1981, Acta paediatrica Scandinavica.